Pfizer’s Q2FY24 revenues declined by 9.8%, marred by a weak season for acute products and the recall of three key brands Magnex, Magnamycin and Zoysn. Gross margins contracted 40bps YoY, but recovered 503bps QoQ to 64.4% as the impact of mandated price cuts on NLEM products was partially offset by better product mix.